Last edition
News about Clinical Trials
Merck is set to showcase new data at ESMO 2025, highlighting advancements in oncology across emerging tumor types and early-stage diseases, with positive survival results from KEYNOTE-905 and KEYNOTE-B96 trials demonstrating the impact of KEYTRUDA (pembrolizumab) in bladder and ovarian cancers.
Clinical Trials | 11/10/2025 | By Dineshwori | 644
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
Clinical Trials | 11/10/2025 | By Dineshwori | 375
Sanofi and Partners Report Positive Phase 2 Results for AlphaMedix in Advanced GEP-NETs
AlphaMedix, which is developed by Orano Med and RadioMedix and now licensed to Sanofi, achieved all primary efficacy endpoints in the phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumours.
Clinical Trials | 08/10/2025 | By Dineshwori | 339
UK Halves Clinical Trial Approval Times Through Major Digital Reforms
Backed by major reforms and new digital platforms at the Medicines and Healthcare products Regulatory Agency (MHRA), the UK has reduced the average clinical trial approval time by more than half — from 91 days to just 41 days.
Clinical Trials | 08/10/2025 | By Dineshwori | 199
WHO launches Global Clinical Trials Forum
The Forum responds to World Health Assembly resolution WHA75.8, which called on WHO to improve the quality and coordination of clinical trials to generate high-quality evidence for health decision-making.
Clinical Trials | 08/10/2025 | By Dineshwori | 123
Merck Expands Tulisokibart Phase-2(b) Trials Across Three Inflammatory Diseases
Tulisokibart is an investigational anti-TL1A monoclonal antibody currently in Phase-3 trials for Ulcerative Colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial spondyloarthritis and Rheumatoid Arthritis.
Clinical Trials | 07/10/2025 | By Dineshwori | 249
Onco3R Therapeutics Advances Phase 1 Trial of Novel SIK3 Inhibitor Targeting Autoimmune Diseases
Pierre Raboisson, CEO and Founder of Onco3R Therapeutics, said that the final results of the Phase 1 trial of O3R-5671 are expected in the first half of 2026.
Clinical Trials | 06/10/2025 | By Dineshwori | 117
WHO Warns of Insufficient Pipeline of Treatments and Diagnostics to Combat Antimicrobial Resistance
The World Health Organization (WHO) has raised the alarm over the shrinking pipeline of new antibacterials and diagnostics, urging greater investment in R&D to tackle the growing threat of antimicrobial resistance (AMR).
Clinical Trials | 03/10/2025 | By Dineshwori | 363
Roche Reports Positive Results from Phase III evERA Breast Cancer Study
Roche has announced positive results from the phase III evERA study evaluating its investigational oral selective oestrogen receptor degrader (SERD), giredestrant, in combination with everolimus in people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.
Clinical Trials | 24/09/2025 | By Dineshwori | 108
Ionis Experimental Drug Zilganersen Shows Promise in Trial for Alexander Disease
Ionis Pharmaceuticals has reported positive topline results from a pivotal study of its experimental drug zilganersen in patients with Alexander disease, a rare, progressive and often fatal neurological disorder.
Clinical Trials | 23/09/2025 | By Darshana | 134
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy